ACG will invest $200 million in its first empty-capsule manufacturing facility in the US

Global pharmaceutical capsule supplier ACG will invest $200 million in a phased investment in its first empty capsule manufacturing in the US.¹ In the first phase, $100 million will go towards funding a hard-shell facility in Atlanta, Georgia, while the second $100 million will support additional capacity in the region. Operations are anticipated to begin in early 2027 and the project is expected to generate more than 200 jobs.

ACG expands capsule manufacturing in the US

The facilities will include manufacturing gelatin and vegetarian (HPMC) hard-shell capsules, with adherence and dedication to global standards and compliance, alongside ACG’s Make it Better commitment.

"ACG has served North America for over 25 years,” stated said Karan Singh, Managing Director, ACG, in an October 20, 2025, press release.¹ “This facility strengthens our ties with customers across the region—bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient, de-risked supply chain. Just as importantly, it lets us respond more quickly and co-develop new innovations through tighter R&D partnerships. It's been a long time coming, and we're glad to say it's here.”

The company also produces barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. Its headquarters is in Piscataway, New Jersey, with operations for manufacturing liquid fill capsules in Chadds Ford, Pennsylvania.

"Atlanta is the right location to execute at scale," added Selwyn Noronha, CEO, ACG Capsules. "Georgia and the City of Atlanta offer a pro-business environment, a strong talent pipeline, world-class connectivity, and reliable infrastructure. Combined with ACG's recent facility builds in Aurangabad (HPMC), Thailand (gelatin), and expansions in Brazil, Croatia and India, we have the operating discipline to begin production quickly and deliver reliable supply for North American customers."

ACG currently has sales and services teams nationwide along with multiple warehouses in the US.

Innovation in Personalized Capsule Machine (PCM)

In May 2025, ACG announced the release of its Personalized Capsule Machine (PCM), a patented technology that enables custom formulations for more individualized supplements.² The technology was created in partnership with the Art of You (AoY), and combines real-time health information with precise dosing and automated capsule production.

“After five years in development, we are thrilled to launch the PCM and collaborate with Art of You on this groundbreaking initiative," Aaron Quinn, senior manager for Europe at Vantage Nutrition, had stated in a press release. "It represents a true leap forward in personalized nutrition. This partnership underscores our commitment to growth through innovation and focus on advancing health solutions globally. With over 1,500 PCM machines planned for deployment across Europe in the next five years and projected revenue of more than €500 million over the next three, this initiative highlights ACG’s leadership in delivering cutting-edge capsule and beadlet technologies to the market.”

Additional features of the PCM include controlled-release coating; advanced bioavailability and absorption; and vegan, tasteless, and microplastic-free materials.

ACG’s response to Titanium dioxide regulation

In August, the European Commission released a working document explaining its support of the continued use of titanium dioxide (TiO₂) in pharmaceuticals.³ TiO₂ is used in 91,000 human medicinal products as a whitener, opacifier, and protective coating, though it was banned as a food additive in 2022 by the EU. The European Medicines Agency (EMA) had released a safety assessment on TiO2 in March, concluding that its carcinogen risk is negligible and alternatives were inferior.

ACG released a statement in response supporting the Commission’s decision. “This is a wise and pragmatic decision for the pharmaceutical sector,” Subhashis Chakraborty, PhD, general manager, head - global product management at ACG Capsules, had stated. “We remain fully committed to supporting the nutraceutical industry in navigating the ongoing ban through innovative TiO₂-free capsule solutions.” ACG also added it was providing education to the industry on the situation and working toward alternatives to TiO₂.

References

1. ACG. ACG to invest $200 million in U.S. hard-shell capsule manufacturing. October 20, 2025. https://www.prnewswire.com/news-releases/acg-to-invest-200-million-in-us-hard-shell-capsule-manufacturing-302589086.html (accessed 2025-10-20).
2. Colli, M. ACG introduces new technology for personalized capsule formulation and production. May 16, 2025. https://www.nutritionaloutlook.com/view/acg-introduces-new-technology-for-personalized-capsule-formulation-and-production (accessed 2025-10-20).
3. McEvoy, E. European Commission Confirms Titanium Dioxide Use in Medicines Following EMA Review. August 15, 2025. https://www.nutritionaloutlook.com/view/european-commission-confirms-titanium-dioxide-use-in-medicines-following-ema-review (accessed 2025-10-20).